Latest Breaking News On - Unmet medical need - Page 1 : comparemela.com

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian mullenChris giordanoJohn frauncesJaved butlerDaniel burkhoffSanjiv shahNasdaq stock marketResearch for the bluhm cardiovascular instituteOrion corporationLifesci advisorsTenax therapeutics incMd northwestern universityTrademark officeCardiovascular research foundation technologyGlobal development

MeiraGTx : Results of a Phase 1, Open-label, Dose-escalation Study of Gene Therapy with AAV2-hAQP1 as Treatment for Grade 2 and 3 Radiation-induced Late Xerostomia and Parotid Gland Hypofunction – The AQUAx Study

Results of a Phase 1, Open-label,Dose-escalation Study of Gene Therapy with AAV2-hAQP1 as Treatment for Grade 2 and 3 Radiation-induced Late Xerostomia and Parotid Gland Hypofunction -.

United statesMichaelt brennanDose escalation studyGene therapyLate xerostomiaParotid gland hypofunctionInduced xerostomiaUnmet medical needStudy designSymptom inventoryChange questionnaireBaseline characteristicsTotal xerostomia questionnaireDry mouthRelatedtreatment emergent adverse eventsXerostomia questionnaire

Cyclo Therapeutics : Corporate Presentation

NASDAQ: CYTH cyclotherapeutics.com Forward-Looking Statements 2 .

United statesSouth africaBenny liuGeraldf coxSharonh hrynkowMichael lisjakKaren mullenCaroline hastingsRita colwellLori gorskiJeffreyl tateUniversity professorNational medal of scienceUniversity of the witwatersrandKantar healthTessellon inc

Cybin Inc : Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc : Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomDoug drysdaleStefan klotterSamir inamdarGabriel fahelExchange commissionPsychiatry researchHealth canadaDrug administrationDepartment of psychiatryCybin incCompany phaseTherapy designationMajor depressive disorderMontgomery asberg depression rating scale

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

TORONTO (BUSINESS WIRE) Mar 13, 2024

United statesUnited kingdomDoug drysdaleGabriel fahelSamir inamdarHealth canadaCompany phaseDepartment of psychiatryPsychiatry researchDrug administrationCybin incExchange commissionBusiness wireTherapy designation acceleratesPath forwardBreakthrough therapy designation